Want to see LUCD full AI Analyst Report?
LUCD Stock Chart & Stats
$1.22
>-$0.01(-1.09%)
At close: 4:00 PM EST
$1.22
>-$0.01(-1.09%)
Day’s Range― - ―
52-Week Range$0.90 - $1.63
Previous CloseN/A
Volume130.18K
Average Volume (3M)1.17M
Market Cap
$217.28M
Enterprise Value$99.46M
Total Cash (Recent Filing)$27.88M
Total Debt (Recent Filing)$26.80M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Aug 17, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding203,066,790
10 Day Avg. Volume1,533,062
30 Day Avg. Volume1,173,347
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)10.16
Price to Sales (P/S)23.61
P/FCF Ratio-2.39
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue19.37
Enterprise Value/Gross Profit-48.40
Enterprise Value/Ebitda-2.25
Forecast
1Y Price Target
$3.95Price Target Upside223.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.24
Revenue Forecast (FY)$7.38M
Bulls Say, Bears Say
Bulls Say
Commercial Traction / Test VolumeSustained test volumes above pre-set targets indicate durable physician adoption and procedure workflow fit. Consistent procedure throughput supports scalable, volume-driven revenue once reimbursement converts and reduces unit-cost risk through higher lab utilization.
VA Federal Supply Schedule ContractA Federal Supply Schedule contract with Medicare-aligned pricing creates a durable, large-volume channel and validated pricing benchmark. Access to ~9M veterans plus initial PO supports predictable institutional demand and reduces dependence on fragmented commercial payer adoption.
Strengthened Cash Runway Via FinancingA sizable equity raise meaningfully extends operating runway and lowers immediate solvency risk, enabling continued commercialization investments, payer engagement and guideline/clinical study execution needed to reach sustainable volume and future reimbursement improvements.
Bears Say
Negative Gross Profit And LossesNegative gross profit signals adverse unit economics; absent higher allowable payments or lower per-test costs, scaling volume will not translate to profitability. Large operating and net losses imply continued dependency on external funding until unit economics improve.
Very High Leverage And Capital-structure RiskA debt-to-equity ratio ~6.7x and history of negative equity create persistent refinancing and interest-rate pressure. High fixed financing costs and covenant/refinancing risk constrain strategic flexibility and raise the likelihood that future funding dilutes shareholders or increases leverage.
Reimbursement, Revenue Recognition And Collections RiskRecognition of only ~14% of billed value due to cash-collection accounting and adjudication volatility limits predictable cash flow. Medicare LCD delays and high denial rates impair revenue convertibility, slowing cash generation and hindering scaling even if clinical demand exists.
Lucid Diagnostics News
LUCD FAQ
What was Lucid Diagnostics Inc.’s price range in the past 12 months?
Lucid Diagnostics Inc. lowest stock price was $0.90 and its highest was $1.63 in the past 12 months.
What is Lucid Diagnostics Inc.’s market cap?
Lucid Diagnostics Inc.’s market cap is $217.28M.
When is Lucid Diagnostics Inc.’s upcoming earnings report date?
Lucid Diagnostics Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 41 days.
How were Lucid Diagnostics Inc.’s earnings last quarter?
Lucid Diagnostics Inc. released its earnings results on May 14, 2026. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.063 by -$0.007.
Is Lucid Diagnostics Inc. overvalued?
According to Wall Street analysts Lucid Diagnostics Inc.’s price is currently Undervalued.
Does Lucid Diagnostics Inc. pay dividends?
Lucid Diagnostics Inc. does not currently pay dividends.
What is Lucid Diagnostics Inc.’s EPS estimate?
Lucid Diagnostics Inc.’s EPS estimate is -0.05.
How many shares outstanding does Lucid Diagnostics Inc. have?
Lucid Diagnostics Inc. has 203,066,790 shares outstanding.
What happened to Lucid Diagnostics Inc.’s price movement after its last earnings report?
Lucid Diagnostics Inc. reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.063. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lucid Diagnostics Inc.?
Currently, no hedge funds are holding shares in LUCD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lucid Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.95 (223.77% Upside)
$3.95 (223.77% Upside)
Hedge Fund Trend
Decreased
By 29.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $245.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.90%
12-Months-Change
Fundamentals
Return on Equity
-370.21%
Trailing 12-Months
Asset Growth
3.92%
Trailing 12-Months
Company Description
Lucid Diagnostics Inc.
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
LUCD Company Deck
LUCD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a mix of constructive commercial and balance-sheet progress (test volume above targets, LBM policy secured, VA contract and initial PO, strengthened pro forma cash position, favorable draft guideline mention) alongside material near-term reimbursement and collection challenges (Medicare LCD delays, conservative revenue recognition practices, adjudication volatility and denials, elevated burn rate). Management expressed confidence and has positioned to scale once Medicare coverage is issued, but the company currently faces meaningful timing and cash-collection risk that keeps fundamentals mixed.View all LUCD earnings summariesLUCD Stock 12 Month Forecast
Average Price Target
$3.95
▲(223.77% Upside)
Technical Analysis
Ownership Overview
5.36% Insiders
3.77% Mutual Funds
4.42% Other Institutional Investors
81.28% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---